What the evidence shows
- A 2011 meta-analysis of ten trials and 699 children found a small but significant improvement in ADHD symptoms with omega-3.
- In that review, supplements with more EPA went with a stronger effect.
- The 2011 authors rated the omega-3 effect as modest compared with psychostimulants, atomoxetine and alpha-2 agonists.
- A 2018 meta-analysis of seven trials and 534 young people found better ADHD symptom scores with omega-3 (g = 0.38).
- In three trials with 214 young people, omega-3 improved attention-related thinking tests (g = 1.09).
- Children and adolescents with ADHD had lower DHA, EPA and total omega-3 levels than comparison groups.
- A 2001 review said a large US study confirmed the main role of psychostimulants for children with ADHD.
Why Researchers Studied Omega-3 in ADHD
ADHD means attention-deficit/hyperactivity disorder. People often search for the best nootropics for ADHD. Omega-3 fatty acids often come up in that search. This article looks only at what pooled human trials report.
A 2011 review gave the reasons for the research. Several studies found different omega-3 levels in people with ADHD. These differences showed up in blood plasma and in red blood cell walls. The comparison group was people without ADHD.
The same review gave possible ways omega-3 might act:
- Omega-3 fatty acids have anti-inflammatory properties.
- They can change how flexible brain cell walls are.
- They can change the fat makeup of those cell walls.
- Changes in cell wall flexibility can alter serotonin and dopamine signals.
The 2018 review began from a different point. Its authors said the role of omega-3 in ADHD was unclear. This applied both to the cause of ADHD and to its care.
How These Studies Work
Both papers are meta-analyses. A meta-analysis pools the results of many studies into one answer.
The trials in these reviews were randomized. This means chance decided who got omega-3 and who did not. The 2011 review used only trials that compared omega-3 with a dummy pill.
The reviews report effect size as g or as a standardized mean difference. Both numbers show how big a difference is in a shared unit. A larger number means a larger difference.
Two omega-3 fatty acids come up often:
- EPA is eicosapentaenoic acid.
- DHA is docosahexaenoic acid.
The 2011 Meta-Analysis: A Small but Significant Effect
This review searched PubMed for trials in children with ADHD symptoms. PubMed is a large medical research database.
What it included: Ten trials with 699 children in total.
Main outcome: The difference in ADHD severity rating scales between groups.
Results:
- Omega-3 showed a small but significant effect on ADHD symptoms.
- Higher EPA content in the supplement went with a stronger effect.
- The review found no evidence of publication bias. Publication bias means positive studies get published more often than negative ones.
- The review found no evidence that trial results differed much from each other.
The authors' conclusion: Omega-3 was modestly effective for ADHD. This was especially true for supplements with more EPA. The effect was modest compared with current ADHD drugs. These drugs include psychostimulants, atomoxetine and alpha-2 agonists.
The authors noted that omega-3 has fairly mild side effects. They said omega-3 may be reasonable as an add-on to standard drugs. They also said it may suit families who decline other drug options. This is the authors' view, not advice from NootroWorld.
The 2018 Meta-Analysis: Symptoms, Attention and Blood Levels
This review looked at children and adolescents with ADHD. It asked two separate questions.
Question 1: Does omega-3 change symptoms and thinking skills?
- Seven randomized trials included 534 young people with ADHD.
- Omega-3 improved ADHD symptom scores (g = 0.38, p < 0.0001).
- Three randomized trials included 214 young people with ADHD.
- In these, omega-3 improved attention-related thinking tests (g = 1.09, p = 0.001).
The authors described these results as omega-3 used alone. This means omega-3 was not combined with other ADHD drugs.
Question 2: Do young people with ADHD have lower omega-3 levels?
This part used case-control studies. These studies compare people with ADHD with people without it. They measured omega-3 in blood and in cheek tissue.
- DHA was lower in youth with ADHD (seven studies, 412 people, g = -0.76, p = 0.0002).
- EPA was lower in youth with ADHD (seven studies, 468 people, g = -0.38, p = 0.0008).
- Total omega-3 was lower in youth with ADHD (six studies, 396 people, g = -0.58, p = 0.0001).
The authors' conclusion: Omega-3 improved symptoms and thinking test results in youth with ADHD. These youth also had low omega-3 levels. The authors said this supports the reasoning for omega-3 as a treatment option.
How Omega-3 Compares With Standard ADHD Drugs
A 2001 review described the drug side of ADHD care. It said a large US government study confirmed a main role for psychostimulants. This study, called the MTA study, focused on children with ADHD.
That 2001 review also made these points:
- ADHD is often a lifelong condition.
- The best care uses several approaches together.
- People respond differently to different psychostimulants.
The 2011 omega-3 review made a direct comparison. It found the omega-3 effect modest next to psychostimulants, atomoxetine and alpha-2 agonists.
What Remains Uncertain
The pooled trials point in one direction. Still, the reviews leave some open points.
- Effect size: The 2011 review called the symptom effect small. Its authors called it modest compared with ADHD drugs.
- Attention results: The large attention effect in 2018 came from three trials with 214 people. The symptom result came from seven trials with 534 people.
- Which omega-3: In 2011, more EPA went with a larger effect. The review linked this to supplement content, not to a single tested product.
- Low levels: The 2018 review found lower omega-3 levels in youth with ADHD. These were comparison studies, not trials of cause and effect.
- Age group: Both reviews studied children or adolescents. The results describe these young groups.
This article does not give dosing advice. It does not make any treatment claim for a single person. Decisions about ADHD care belong with a qualified clinician.
Sources
- Omega-3 fatty acid supplementation for the treatment of children with attention-deficit/hyperactivity disorder symptomatology: systematic review and meta-analysis. Journal of the American Academy of Child and Adolescent Psychiatry, 2011
- Omega-3 Polyunsaturated Fatty Acids in Youths with Attention Deficit Hyperactivity Disorder: a Systematic Review and Meta-Analysis of Clinical Trials and Biological Studies. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018
- Present and future pharmacotherapeutic options for adult attention deficit/hyperactivity disorder. Expert opinion on pharmacotherapy, 2001
About this article
NootroWorld publishes research summaries, not medical advice. This article describes what studies have and have not established; it does not tell you what to take. Supplements can interact with medication, pregnancy and existing health conditions, and study populations often differ from your own situation. Discuss any personal decision with a qualified healthcare professional.
